Literature DB >> 20421580

Clinical and prognostic subforms of new daily-persistent headache.

M S Robbins1, B M Grosberg, U Napchan, S C Crystal, R B Lipton.   

Abstract

BACKGROUND: According to the International Classification of Headache Disorders (ICHD)-2, primary daily headaches unremitting from onset are classified as new daily-persistent headache (NDPH) only if migraine features are absent. When migraine features are present, classification is problematic.
METHODS: We developed a revised NDPH definition not excluding migraine features (NDPH-R), and applied it to consecutive patients seen at the Montefiore Headache Center. We divided this group into patients meeting ICHD-2 criteria (NDPH-ICHD) and those with too many migraine features for ICHD-2 (NDPH-mf). We compared clinical and demographic features in these groups, identifying 3 prognostic subgroups: persisting, remitting, and relapsing-remitting. Remitting and relapsing-remitting patients were combined into a nonpersisting group.
RESULTS: Of 71 NDPH-R patients, 31 (43.7%) also met NDPH-ICHD-2 criteria. The NDPH-mf and the NDPH-ICHD-2 groups were similar in most clinical features though the NDPH-mf group was younger, included more women, and had a higher frequency of depression. The groups were similar in the prevalence of allodynia, triptan responsiveness, and prognosis. NDPH-R prognostic subforms were also very similar, although the persisting subform was more likely to be of white race, to have anxiety or depression, and to have a younger onset age.
CONCLUSIONS: Current International Classification of Headache Disorders (ICHD)-2 criteria exclude the majority of patients with primary headache unremitting from onset. The proposed criteria for revised new daily-persistent headache definition not excluding migraine features (NDPH-R) classify these patients into a relatively homogeneous group based on demographics, clinical features, and prognosis. Both new daily-persistent headache with too many migraine features for ICHD-2 and new daily-persistent headache meeting ICHD-2 criteria include patients in equal proportions that fall into the persisting, remitting, and relapsing-remitting subgroups. Our criteria for NDPH-R should be considered for inclusion in ICHD-3.

Entities:  

Mesh:

Year:  2010        PMID: 20421580      PMCID: PMC3462554          DOI: 10.1212/WNL.0b013e3181dad5de

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  23 in total

Review 1.  New daily persistent headache.

Authors:  Peter J Goadsby; Christopher Boes
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-06       Impact factor: 10.154

2.  The International Classification of Headache Disorders: 2nd edition.

Authors: 
Journal:  Cephalalgia       Date:  2004       Impact factor: 6.292

3.  The PHQ-9: validity of a brief depression severity measure.

Authors:  K Kroenke; R L Spitzer; J B Williams
Journal:  J Gen Intern Med       Date:  2001-09       Impact factor: 5.128

4.  The clinical characteristics of new daily persistent headache.

Authors:  D Li; T D Rozen
Journal:  Cephalalgia       Date:  2002-02       Impact factor: 6.292

5.  Prevalence of new daily persistent headache in the general population. The Akershus study of chronic headache.

Authors:  R B Grande; K Aaseth; C Lundqvist; M B Russell
Journal:  Cephalalgia       Date:  2009-11       Impact factor: 6.292

6.  Misdiagnosis of spontaneous intracranial hypotension.

Authors:  Wouter I Schievink
Journal:  Arch Neurol       Date:  2003-12

Review 7.  New daily persistent headache in children and adults.

Authors:  Kenneth J Mack
Journal:  Curr Pain Headache Rep       Date:  2009-02

8.  New daily persistent headache in the paediatric population.

Authors:  E Kung; S J Tepper; A M Rapoport; F D Sheftell; M E Bigal
Journal:  Cephalalgia       Date:  2009-01       Impact factor: 6.292

9.  Cutaneous allodynia in the migraine population.

Authors:  Richard B Lipton; Marcelo E Bigal; Sait Ashina; Rami Burstein; Stephen Silberstein; Michael L Reed; Daniel Serrano; Walter F Stewart
Journal:  Ann Neurol       Date:  2008-02       Impact factor: 10.422

Review 10.  Spontaneous low cerebrospinal pressure/volume headaches.

Authors:  Bahram Mokri
Journal:  Curr Neurol Neurosci Rep       Date:  2004-03       Impact factor: 5.081

View more
  22 in total

Review 1.  Tension-type headache mimics.

Authors:  Sara C Crystal; Matthew S Robbins
Journal:  Curr Pain Headache Rep       Date:  2011-12

Review 2.  New Daily Persistent Headache: a Diagnostic and Therapeutic Odyssey.

Authors:  Emily J Riddle; Jonathan H Smith
Journal:  Curr Neurol Neurosci Rep       Date:  2019-03-19       Impact factor: 5.081

Review 3.  New daily persistent headache and potential new therapeutic agents.

Authors:  Shivang G Joshi; Paul G Mathew; Herbert G Markley
Journal:  Curr Neurol Neurosci Rep       Date:  2014-02       Impact factor: 5.081

Review 4.  New daily persistent headache: an update.

Authors:  Todd D Rozen
Journal:  Curr Pain Headache Rep       Date:  2014-07

Review 5.  New daily-persistent headache versus tension-type headache.

Authors:  Matthew S Robbins; Sara C Crystal
Journal:  Curr Pain Headache Rep       Date:  2010-12

Review 6.  New daily persistent headache: controversy in the diagnostic criteria.

Authors:  William B Young
Journal:  Curr Pain Headache Rep       Date:  2011-02

7.  Does NDPH exist? Some clinical considerations.

Authors:  G C Manzoni; P Torelli
Journal:  Neurol Sci       Date:  2011-05       Impact factor: 3.307

Review 8.  The diagnosis and treatment of chronic migraine.

Authors:  Mark W Weatherall
Journal:  Ther Adv Chronic Dis       Date:  2015-05       Impact factor: 5.091

9.  [Different headache forms of chapter 4 of the International Headache Classification].

Authors:  A Göbel; A Heinze; H Göbel
Journal:  Schmerz       Date:  2012-12       Impact factor: 1.107

10.  Chronic headache with vasospasm treated with nimodipine.

Authors:  Daniela Pimenta Silva; Maria Fátima Soares; Vanessa Almeida; Ana Catarina Fonseca
Journal:  J Neurol       Date:  2019-03-25       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.